nodes	percent_of_prediction	percent_of_DWPC	metapath
Afatinib—ABCG2—Teniposide—lymphatic system cancer	0.231	0.333	CbGbCtD
Afatinib—ABCG2—Mitoxantrone—lymphatic system cancer	0.162	0.233	CbGbCtD
Afatinib—ABCG2—Vincristine—lymphatic system cancer	0.111	0.16	CbGbCtD
Afatinib—ABCG2—Methotrexate—lymphatic system cancer	0.0674	0.097	CbGbCtD
Afatinib—ABCB1—Mitoxantrone—lymphatic system cancer	0.0583	0.084	CbGbCtD
Afatinib—ABCB1—Vincristine—lymphatic system cancer	0.0401	0.0578	CbGbCtD
Afatinib—ABCB1—Methotrexate—lymphatic system cancer	0.0243	0.035	CbGbCtD
Afatinib—Pulmonary toxicity—Fludarabine—lymphatic system cancer	0.0163	0.056	CcSEcCtD
Afatinib—Disease progression—Carmustine—lymphatic system cancer	0.0108	0.0373	CcSEcCtD
Afatinib—Pulmonary toxicity—Carmustine—lymphatic system cancer	0.0104	0.0358	CcSEcCtD
Afatinib—Mucosal inflammation—Teniposide—lymphatic system cancer	0.0076	0.0261	CcSEcCtD
Afatinib—Mucosal inflammation—Fludarabine—lymphatic system cancer	0.00668	0.023	CcSEcCtD
Afatinib—Paronychia—Methotrexate—lymphatic system cancer	0.00632	0.0217	CcSEcCtD
Afatinib—Blood potassium decreased—Mitoxantrone—lymphatic system cancer	0.00579	0.0199	CcSEcCtD
Afatinib—ERBB2—Ribavirin—Fludarabine—lymphatic system cancer	0.00511	0.358	CbGdCrCtD
Afatinib—Mucosal inflammation—Bleomycin—lymphatic system cancer	0.0049	0.0168	CcSEcCtD
Afatinib—Pulmonary toxicity—Methotrexate—lymphatic system cancer	0.00483	0.0166	CcSEcCtD
Afatinib—ERBB2—Ribavirin—Cytarabine—lymphatic system cancer	0.00483	0.338	CbGdCrCtD
Afatinib—ERBB2—Podofilox—Teniposide—lymphatic system cancer	0.00435	0.304	CbGdCrCtD
Afatinib—Mucosal inflammation—Mitoxantrone—lymphatic system cancer	0.00398	0.0137	CcSEcCtD
Afatinib—Interstitial lung disease—Bleomycin—lymphatic system cancer	0.00383	0.0132	CcSEcCtD
Afatinib—Sepsis—Teniposide—lymphatic system cancer	0.00365	0.0125	CcSEcCtD
Afatinib—Interstitial lung disease—Carmustine—lymphatic system cancer	0.00334	0.0115	CcSEcCtD
Afatinib—Interstitial lung disease—Mitoxantrone—lymphatic system cancer	0.00311	0.0107	CcSEcCtD
Afatinib—Cystitis noninfective—Bleomycin—lymphatic system cancer	0.00265	0.0091	CcSEcCtD
Afatinib—Cystitis—Bleomycin—lymphatic system cancer	0.00262	0.009	CcSEcCtD
Afatinib—Alopecia—Mechlorethamine—lymphatic system cancer	0.00253	0.0087	CcSEcCtD
Afatinib—Dehydration—Fludarabine—lymphatic system cancer	0.0025	0.00858	CcSEcCtD
Afatinib—Bladder pain—Bleomycin—lymphatic system cancer	0.00245	0.00842	CcSEcCtD
Afatinib—Stomatitis—Teniposide—lymphatic system cancer	0.00229	0.00788	CcSEcCtD
Afatinib—Upper respiratory tract infection—Fludarabine—lymphatic system cancer	0.00216	0.00741	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Mechlorethamine—lymphatic system cancer	0.00211	0.00725	CcSEcCtD
Afatinib—Pneumonia—Fludarabine—lymphatic system cancer	0.00208	0.00715	CcSEcCtD
Afatinib—Sepsis—Carmustine—lymphatic system cancer	0.00205	0.00706	CcSEcCtD
Afatinib—Mouth ulceration—Vincristine—lymphatic system cancer	0.00204	0.00702	CcSEcCtD
Afatinib—Renal failure—Fludarabine—lymphatic system cancer	0.00203	0.00699	CcSEcCtD
Afatinib—Infection—Mechlorethamine—lymphatic system cancer	0.00202	0.00695	CcSEcCtD
Afatinib—Stomatitis—Fludarabine—lymphatic system cancer	0.00202	0.00693	CcSEcCtD
Afatinib—Urinary tract infection—Fludarabine—lymphatic system cancer	0.00201	0.00691	CcSEcCtD
Afatinib—Mucosal inflammation—Methotrexate—lymphatic system cancer	0.00198	0.0068	CcSEcCtD
Afatinib—Skin disorder—Mechlorethamine—lymphatic system cancer	0.00198	0.0068	CcSEcCtD
Afatinib—Epistaxis—Fludarabine—lymphatic system cancer	0.00195	0.0067	CcSEcCtD
Afatinib—Sepsis—Mitoxantrone—lymphatic system cancer	0.00191	0.00656	CcSEcCtD
Afatinib—Alopecia—Teniposide—lymphatic system cancer	0.00187	0.00642	CcSEcCtD
Afatinib—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.00177	0.00608	CcSEcCtD
Afatinib—Alopecia—Fludarabine—lymphatic system cancer	0.00164	0.00564	CcSEcCtD
Afatinib—Malnutrition—Fludarabine—lymphatic system cancer	0.00162	0.00556	CcSEcCtD
Afatinib—Hypokalaemia—Carmustine—lymphatic system cancer	0.00156	0.00537	CcSEcCtD
Afatinib—Interstitial lung disease—Methotrexate—lymphatic system cancer	0.00155	0.00532	CcSEcCtD
Afatinib—Weight decreased—Bleomycin—lymphatic system cancer	0.00154	0.00529	CcSEcCtD
Afatinib—Pneumonia—Bleomycin—lymphatic system cancer	0.00153	0.00524	CcSEcCtD
Afatinib—Dehydration—Vincristine—lymphatic system cancer	0.00153	0.00524	CcSEcCtD
Afatinib—Infection—Teniposide—lymphatic system cancer	0.00149	0.00512	CcSEcCtD
Afatinib—Dehydration—Mitoxantrone—lymphatic system cancer	0.00149	0.0051	CcSEcCtD
Afatinib—Stomatitis—Bleomycin—lymphatic system cancer	0.00148	0.00508	CcSEcCtD
Afatinib—Aspartate aminotransferase increased—Vincristine—lymphatic system cancer	0.00148	0.00507	CcSEcCtD
Afatinib—Hypokalaemia—Mitoxantrone—lymphatic system cancer	0.00145	0.00499	CcSEcCtD
Afatinib—Pruritus—Mechlorethamine—lymphatic system cancer	0.00144	0.00495	CcSEcCtD
Afatinib—Aspartate aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.00144	0.00494	CcSEcCtD
Afatinib—Cough—Fludarabine—lymphatic system cancer	0.00141	0.00485	CcSEcCtD
Afatinib—Alanine aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.00141	0.00484	CcSEcCtD
Afatinib—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00139	0.00479	CcSEcCtD
Afatinib—Dyspnoea—Teniposide—lymphatic system cancer	0.00134	0.0046	CcSEcCtD
Afatinib—Pneumonia—Carmustine—lymphatic system cancer	0.00133	0.00458	CcSEcCtD
Afatinib—Infection—Fludarabine—lymphatic system cancer	0.00131	0.0045	CcSEcCtD
Afatinib—Decreased appetite—Teniposide—lymphatic system cancer	0.00131	0.00448	CcSEcCtD
Afatinib—Renal failure—Carmustine—lymphatic system cancer	0.0013	0.00447	CcSEcCtD
Afatinib—Vomiting—Mechlorethamine—lymphatic system cancer	0.0013	0.00445	CcSEcCtD
Afatinib—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00129	0.00445	CcSEcCtD
Afatinib—Stomatitis—Carmustine—lymphatic system cancer	0.00129	0.00443	CcSEcCtD
Afatinib—Urinary tract infection—Carmustine—lymphatic system cancer	0.00129	0.00442	CcSEcCtD
Afatinib—Rash—Mechlorethamine—lymphatic system cancer	0.00128	0.00441	CcSEcCtD
Afatinib—Upper respiratory tract infection—Mitoxantrone—lymphatic system cancer	0.00128	0.00441	CcSEcCtD
Afatinib—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00128	0.00441	CcSEcCtD
Afatinib—Weight decreased—Vincristine—lymphatic system cancer	0.00128	0.00441	CcSEcCtD
Afatinib—Pneumonia—Vincristine—lymphatic system cancer	0.00127	0.00437	CcSEcCtD
Afatinib—Weight decreased—Mitoxantrone—lymphatic system cancer	0.00125	0.00429	CcSEcCtD
Afatinib—Pneumonia—Mitoxantrone—lymphatic system cancer	0.00124	0.00425	CcSEcCtD
Afatinib—Stomatitis—Vincristine—lymphatic system cancer	0.00123	0.00423	CcSEcCtD
Afatinib—Renal failure—Mitoxantrone—lymphatic system cancer	0.00121	0.00416	CcSEcCtD
Afatinib—Nausea—Mechlorethamine—lymphatic system cancer	0.00121	0.00416	CcSEcCtD
Afatinib—Alopecia—Bleomycin—lymphatic system cancer	0.0012	0.00413	CcSEcCtD
Afatinib—Stomatitis—Mitoxantrone—lymphatic system cancer	0.0012	0.00412	CcSEcCtD
Afatinib—Conjunctivitis—Mitoxantrone—lymphatic system cancer	0.0012	0.00411	CcSEcCtD
Afatinib—Urinary tract infection—Mitoxantrone—lymphatic system cancer	0.0012	0.00411	CcSEcCtD
Afatinib—Body temperature increased—Teniposide—lymphatic system cancer	0.00119	0.00408	CcSEcCtD
Afatinib—Dyspnoea—Fludarabine—lymphatic system cancer	0.00118	0.00404	CcSEcCtD
Afatinib—Connective tissue disorder—Carmustine—lymphatic system cancer	0.00117	0.00401	CcSEcCtD
Afatinib—Dyspepsia—Fludarabine—lymphatic system cancer	0.00116	0.00399	CcSEcCtD
Afatinib—Decreased appetite—Fludarabine—lymphatic system cancer	0.00115	0.00394	CcSEcCtD
Afatinib—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00114	0.00391	CcSEcCtD
Afatinib—Fatigue—Fludarabine—lymphatic system cancer	0.00114	0.00391	CcSEcCtD
Afatinib—Constipation—Fludarabine—lymphatic system cancer	0.00113	0.00388	CcSEcCtD
Afatinib—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00112	0.00385	CcSEcCtD
Afatinib—Connective tissue disorder—Vincristine—lymphatic system cancer	0.00112	0.00383	CcSEcCtD
Afatinib—Urethral disorder—Vincristine—lymphatic system cancer	0.00111	0.00382	CcSEcCtD
Afatinib—Eye disorder—Carmustine—lymphatic system cancer	0.00111	0.00382	CcSEcCtD
Afatinib—Asthenia—Teniposide—lymphatic system cancer	0.00108	0.0037	CcSEcCtD
Afatinib—Cystitis noninfective—Methotrexate—lymphatic system cancer	0.00107	0.00368	CcSEcCtD
Afatinib—Pruritus—Teniposide—lymphatic system cancer	0.00106	0.00365	CcSEcCtD
Afatinib—Cystitis—Methotrexate—lymphatic system cancer	0.00106	0.00364	CcSEcCtD
Afatinib—Alopecia—Carmustine—lymphatic system cancer	0.00105	0.00361	CcSEcCtD
Afatinib—Body temperature increased—Fludarabine—lymphatic system cancer	0.00104	0.00358	CcSEcCtD
Afatinib—Mental disorder—Carmustine—lymphatic system cancer	0.00104	0.00358	CcSEcCtD
Afatinib—Malnutrition—Carmustine—lymphatic system cancer	0.00103	0.00356	CcSEcCtD
Afatinib—Cough—Bleomycin—lymphatic system cancer	0.00103	0.00355	CcSEcCtD
Afatinib—Diarrhoea—Teniposide—lymphatic system cancer	0.00103	0.00353	CcSEcCtD
Afatinib—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00102	0.00351	CcSEcCtD
Afatinib—Alopecia—Vincristine—lymphatic system cancer	0.001	0.00345	CcSEcCtD
Afatinib—Back pain—Carmustine—lymphatic system cancer	0.001	0.00344	CcSEcCtD
Afatinib—Mental disorder—Vincristine—lymphatic system cancer	0.000994	0.00342	CcSEcCtD
Afatinib—Mouth ulceration—Methotrexate—lymphatic system cancer	0.000991	0.00341	CcSEcCtD
Afatinib—Bladder pain—Methotrexate—lymphatic system cancer	0.000991	0.00341	CcSEcCtD
Afatinib—Alopecia—Mitoxantrone—lymphatic system cancer	0.000977	0.00336	CcSEcCtD
Afatinib—Infection—Bleomycin—lymphatic system cancer	0.000961	0.0033	CcSEcCtD
Afatinib—Back pain—Vincristine—lymphatic system cancer	0.000956	0.00328	CcSEcCtD
Afatinib—Vomiting—Teniposide—lymphatic system cancer	0.000955	0.00328	CcSEcCtD
Afatinib—Sepsis—Methotrexate—lymphatic system cancer	0.000952	0.00327	CcSEcCtD
Afatinib—Asthenia—Fludarabine—lymphatic system cancer	0.000947	0.00325	CcSEcCtD
Afatinib—Rash—Teniposide—lymphatic system cancer	0.000947	0.00325	CcSEcCtD
Afatinib—Dermatitis—Teniposide—lymphatic system cancer	0.000946	0.00325	CcSEcCtD
Afatinib—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000942	0.00324	CcSEcCtD
Afatinib—Headache—Teniposide—lymphatic system cancer	0.000941	0.00323	CcSEcCtD
Afatinib—Pruritus—Fludarabine—lymphatic system cancer	0.000934	0.00321	CcSEcCtD
Afatinib—Back pain—Mitoxantrone—lymphatic system cancer	0.000931	0.0032	CcSEcCtD
Afatinib—Diarrhoea—Fludarabine—lymphatic system cancer	0.000903	0.0031	CcSEcCtD
Afatinib—Nausea—Teniposide—lymphatic system cancer	0.000892	0.00306	CcSEcCtD
Afatinib—Dyspnoea—Bleomycin—lymphatic system cancer	0.000863	0.00296	CcSEcCtD
Afatinib—Decreased appetite—Bleomycin—lymphatic system cancer	0.000841	0.00289	CcSEcCtD
Afatinib—Cough—Mitoxantrone—lymphatic system cancer	0.00084	0.00288	CcSEcCtD
Afatinib—Infection—Carmustine—lymphatic system cancer	0.000839	0.00288	CcSEcCtD
Afatinib—Vomiting—Fludarabine—lymphatic system cancer	0.000839	0.00288	CcSEcCtD
Afatinib—Rash—Fludarabine—lymphatic system cancer	0.000832	0.00286	CcSEcCtD
Afatinib—Dermatitis—Fludarabine—lymphatic system cancer	0.000831	0.00286	CcSEcCtD
Afatinib—Headache—Fludarabine—lymphatic system cancer	0.000827	0.00284	CcSEcCtD
Afatinib—Infection—Vincristine—lymphatic system cancer	0.000801	0.00275	CcSEcCtD
Afatinib—Nervous system disorder—Vincristine—lymphatic system cancer	0.000791	0.00272	CcSEcCtD
Afatinib—Nausea—Fludarabine—lymphatic system cancer	0.000784	0.00269	CcSEcCtD
Afatinib—Infection—Mitoxantrone—lymphatic system cancer	0.00078	0.00268	CcSEcCtD
Afatinib—Body temperature increased—Bleomycin—lymphatic system cancer	0.000765	0.00263	CcSEcCtD
Afatinib—Insomnia—Carmustine—lymphatic system cancer	0.000764	0.00262	CcSEcCtD
Afatinib—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000763	0.00262	CcSEcCtD
Afatinib—Dyspnoea—Carmustine—lymphatic system cancer	0.000753	0.00259	CcSEcCtD
Afatinib—Decreased appetite—Carmustine—lymphatic system cancer	0.000734	0.00252	CcSEcCtD
Afatinib—Insomnia—Vincristine—lymphatic system cancer	0.000729	0.00251	CcSEcCtD
Afatinib—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000729	0.00251	CcSEcCtD
Afatinib—Constipation—Carmustine—lymphatic system cancer	0.000722	0.00248	CcSEcCtD
Afatinib—Decreased appetite—Vincristine—lymphatic system cancer	0.000701	0.00241	CcSEcCtD
Afatinib—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.0007	0.0024	CcSEcCtD
Afatinib—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000696	0.00239	CcSEcCtD
Afatinib—Fatigue—Vincristine—lymphatic system cancer	0.000695	0.00239	CcSEcCtD
Afatinib—Asthenia—Bleomycin—lymphatic system cancer	0.000694	0.00239	CcSEcCtD
Afatinib—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000691	0.00237	CcSEcCtD
Afatinib—Constipation—Vincristine—lymphatic system cancer	0.000689	0.00237	CcSEcCtD
Afatinib—Pruritus—Bleomycin—lymphatic system cancer	0.000685	0.00235	CcSEcCtD
Afatinib—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000683	0.00234	CcSEcCtD
Afatinib—Fatigue—Mitoxantrone—lymphatic system cancer	0.000677	0.00233	CcSEcCtD
Afatinib—Constipation—Mitoxantrone—lymphatic system cancer	0.000671	0.00231	CcSEcCtD
Afatinib—Body temperature increased—Carmustine—lymphatic system cancer	0.000668	0.00229	CcSEcCtD
Afatinib—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000639	0.0022	CcSEcCtD
Afatinib—Body temperature increased—Vincristine—lymphatic system cancer	0.000637	0.00219	CcSEcCtD
Afatinib—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000621	0.00213	CcSEcCtD
Afatinib—Pneumonia—Methotrexate—lymphatic system cancer	0.000617	0.00212	CcSEcCtD
Afatinib—Vomiting—Bleomycin—lymphatic system cancer	0.000615	0.00211	CcSEcCtD
Afatinib—Infestation NOS—Methotrexate—lymphatic system cancer	0.000613	0.00211	CcSEcCtD
Afatinib—Infestation—Methotrexate—lymphatic system cancer	0.000613	0.00211	CcSEcCtD
Afatinib—Rash—Bleomycin—lymphatic system cancer	0.00061	0.0021	CcSEcCtD
Afatinib—Dermatitis—Bleomycin—lymphatic system cancer	0.00061	0.00209	CcSEcCtD
Afatinib—Asthenia—Carmustine—lymphatic system cancer	0.000606	0.00208	CcSEcCtD
Afatinib—Renal failure—Methotrexate—lymphatic system cancer	0.000603	0.00207	CcSEcCtD
Afatinib—Stomatitis—Methotrexate—lymphatic system cancer	0.000598	0.00205	CcSEcCtD
Afatinib—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000596	0.00205	CcSEcCtD
Afatinib—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.00058	0.00199	CcSEcCtD
Afatinib—Epistaxis—Methotrexate—lymphatic system cancer	0.000579	0.00199	CcSEcCtD
Afatinib—Asthenia—Vincristine—lymphatic system cancer	0.000578	0.00199	CcSEcCtD
Afatinib—Diarrhoea—Carmustine—lymphatic system cancer	0.000578	0.00199	CcSEcCtD
Afatinib—Nausea—Bleomycin—lymphatic system cancer	0.000575	0.00197	CcSEcCtD
Afatinib—Asthenia—Mitoxantrone—lymphatic system cancer	0.000563	0.00194	CcSEcCtD
Afatinib—Dizziness—Carmustine—lymphatic system cancer	0.000559	0.00192	CcSEcCtD
Afatinib—Diarrhoea—Vincristine—lymphatic system cancer	0.000552	0.0019	CcSEcCtD
Afatinib—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000544	0.00187	CcSEcCtD
Afatinib—Urethral disorder—Methotrexate—lymphatic system cancer	0.00054	0.00185	CcSEcCtD
Afatinib—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000537	0.00185	CcSEcCtD
Afatinib—Vomiting—Carmustine—lymphatic system cancer	0.000537	0.00184	CcSEcCtD
Afatinib—Dizziness—Vincristine—lymphatic system cancer	0.000533	0.00183	CcSEcCtD
Afatinib—Rash—Carmustine—lymphatic system cancer	0.000533	0.00183	CcSEcCtD
Afatinib—Dermatitis—Carmustine—lymphatic system cancer	0.000532	0.00183	CcSEcCtD
Afatinib—Headache—Carmustine—lymphatic system cancer	0.000529	0.00182	CcSEcCtD
Afatinib—Eye disorder—Methotrexate—lymphatic system cancer	0.000515	0.00177	CcSEcCtD
Afatinib—Vomiting—Vincristine—lymphatic system cancer	0.000513	0.00176	CcSEcCtD
Afatinib—Rash—Vincristine—lymphatic system cancer	0.000508	0.00175	CcSEcCtD
Afatinib—Dermatitis—Vincristine—lymphatic system cancer	0.000508	0.00174	CcSEcCtD
Afatinib—Headache—Vincristine—lymphatic system cancer	0.000505	0.00174	CcSEcCtD
Afatinib—Nausea—Carmustine—lymphatic system cancer	0.000502	0.00172	CcSEcCtD
Afatinib—Vomiting—Mitoxantrone—lymphatic system cancer	0.000499	0.00172	CcSEcCtD
Afatinib—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000496	0.0017	CcSEcCtD
Afatinib—Rash—Mitoxantrone—lymphatic system cancer	0.000495	0.0017	CcSEcCtD
Afatinib—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000495	0.0017	CcSEcCtD
Afatinib—Headache—Mitoxantrone—lymphatic system cancer	0.000492	0.00169	CcSEcCtD
Afatinib—Alopecia—Methotrexate—lymphatic system cancer	0.000487	0.00167	CcSEcCtD
Afatinib—Mental disorder—Methotrexate—lymphatic system cancer	0.000482	0.00166	CcSEcCtD
Afatinib—Malnutrition—Methotrexate—lymphatic system cancer	0.000479	0.00165	CcSEcCtD
Afatinib—Nausea—Vincristine—lymphatic system cancer	0.000479	0.00165	CcSEcCtD
Afatinib—Dysgeusia—Methotrexate—lymphatic system cancer	0.000469	0.00161	CcSEcCtD
Afatinib—Nausea—Mitoxantrone—lymphatic system cancer	0.000466	0.0016	CcSEcCtD
Afatinib—Back pain—Methotrexate—lymphatic system cancer	0.000464	0.00159	CcSEcCtD
Afatinib—Cough—Methotrexate—lymphatic system cancer	0.000418	0.00144	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000405	0.00139	CcSEcCtD
Afatinib—Infection—Methotrexate—lymphatic system cancer	0.000389	0.00134	CcSEcCtD
Afatinib—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000384	0.00132	CcSEcCtD
Afatinib—Skin disorder—Methotrexate—lymphatic system cancer	0.00038	0.00131	CcSEcCtD
Afatinib—Insomnia—Methotrexate—lymphatic system cancer	0.000354	0.00122	CcSEcCtD
Afatinib—Dyspnoea—Methotrexate—lymphatic system cancer	0.000349	0.0012	CcSEcCtD
Afatinib—Dyspepsia—Methotrexate—lymphatic system cancer	0.000344	0.00118	CcSEcCtD
Afatinib—Decreased appetite—Methotrexate—lymphatic system cancer	0.00034	0.00117	CcSEcCtD
Afatinib—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000338	0.00116	CcSEcCtD
Afatinib—Fatigue—Methotrexate—lymphatic system cancer	0.000337	0.00116	CcSEcCtD
Afatinib—Body temperature increased—Methotrexate—lymphatic system cancer	0.000309	0.00106	CcSEcCtD
Afatinib—Asthenia—Methotrexate—lymphatic system cancer	0.000281	0.000964	CcSEcCtD
Afatinib—Pruritus—Methotrexate—lymphatic system cancer	0.000277	0.000951	CcSEcCtD
Afatinib—Diarrhoea—Methotrexate—lymphatic system cancer	0.000268	0.00092	CcSEcCtD
Afatinib—Dizziness—Methotrexate—lymphatic system cancer	0.000259	0.000889	CcSEcCtD
Afatinib—Vomiting—Methotrexate—lymphatic system cancer	0.000249	0.000855	CcSEcCtD
Afatinib—Rash—Methotrexate—lymphatic system cancer	0.000247	0.000847	CcSEcCtD
Afatinib—Dermatitis—Methotrexate—lymphatic system cancer	0.000246	0.000847	CcSEcCtD
Afatinib—Headache—Methotrexate—lymphatic system cancer	0.000245	0.000842	CcSEcCtD
Afatinib—Nausea—Methotrexate—lymphatic system cancer	0.000232	0.000798	CcSEcCtD
